1.22Open1.22Pre Close0 Volume113 Open Interest150.00Strike Price0.00Turnover152.55%IV36.49%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier12DDays to Expiry1.22Extrinsic Value100Contract SizeAmericanOptions Type-0.0412Delta0.0013Gamma192.03Leverage Ratio-0.2266Theta-0.0034Rho-7.91Eff Leverage0.0380Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet